uploads///Graph

How Sanofi’s Specialty Care Franchises Performed in Q1

By

Updated

Revenue performance

In the first quarter, Sanofi’s (SNY) Specialty Care Franchise reported net sales of 2.33 billion euros, a YoY rise of 31.2% on a CER (constant exchange rate) basis. Of these sales, 2.02 billion euros were earned from developed markets, a YoY rise of 30.8% on a CER basis. Emerging markets contributed the remaining 308 million euros in sales, a YoY rise of 33.6% on a CER basis.

Article continues below advertisement

Performance by franchise

In the first quarter, Sanofi’s Rare Disease Franchise reported net sales of 766 million euros, a YoY rise of 10.1% on a CER basis. Of these sales, 613 million euros were earned from developed markets, a YoY rise of 3.9% on a CER basis. Emerging markets contributed the remaining 153 million euros in sales, a YoY rise of 37.2% on a CER basis.

According to Sanofi’s first-quarter earnings press release, this performance was mainly driven by a solid uptake of Gaucher therapies and Cerezyme and Cerdelga in emerging markets and Europe, respectively. The company also benefitted from accruals of treatment-naïve Pompe and Fabry disease patients, which in turn pushed up sales of drugs such as Myozyme/Lumizyme and Fabrazyme, in the first quarter.

In the first quarter, Sanofi’s Multiple Sclerosis franchise reported net sales of 529 million euros, a YoY rise of 5.9% on a CER basis. Of these sales, 507 million euros were earned from developed markets, a YoY rise of 4.6% on a CER basis. Emerging markets contributed the remaining 22 million euros in sales, a YoY rise of 41.2% on a CER basis. This performance was driven by an 11.9% YoY rise in Aubagio’s sales, partly offset by a 15.2% decline in Lemtrada sales in the first quarter. In the first quarter, Aubagio reported sales of 437 million euros, of which 309 million euros were from the US market, 98 million euros were from Europe, and 16 million euros from emerging markets.

Advertisement

More From Market Realist